This document provides a summary of statements made in a presentation by VeriTeQ Corporation. It includes forward-looking statements about VeriTeQ's proposed name change, reverse stock split, commercialization activities, market opportunities, strategy, competition, FDA regulation, and partnership opportunities. The document cautions that VeriTeQ's actual results could differ from these statements due to various risks and uncertainties. It also provides background on VeriTeQ, including its acquisition of intellectual property for implantable RFID technology in healthcare. The document summarizes VeriTeQ's business areas in medical device UDI compliance and biosensing technologies for radiation dosimetry.

1. April 2014

2. Safe Harbor Statement
2
Statements made in this presentation regarding VeriTeQ Corporation (“VeriTeQ” or “Company”) and VeriTeQ that
are not historical facts are forward-looking statements based on our current expectations, assumptions, estimates
and projections about VeriTeQ and our industry. These forward-looking statements are subject to risks and
uncertainties that could cause actual future events or results to differ materially from such statements. These
forward-looking statements include, without limitation, statements about our proposed name change and reverse
stock split, our commercialization activities, market opportunities, our strategy, our competition, FDA regulation,
partnership opportunities, market penetration, and all other forward-looking statements. You should not place
undue reliance on any of the forward-looking statements made in this presentation. Our actual results could differ
materially from those expressed or implied by these forward-looking statements as a result of various factors,
including risks and uncertainties related to the timing or successful completion of our product commercialization
activities, VeriTeQ’s ability to raise capital, and other various risks and uncertainties. Additional information about
these and other factors that could affect VeriTeQ’s business is set forth in its various filings with the Securities and
Exchange Commission, including those set forth in its Form 10-K filed on June 28, 2013, and Forms 10-Q filed
on July 16, 2013 and November 14, 2013, under the caption "Risk Factors." The Company undertakes no
obligation to update publicly any forward-looking statements for any reason, even if new information becomes
available or other events occur in the future.
This presentation does not constitute a prospectus or form part of any offer or invitation to sell or issue, or any
solicitation of any offer to purchase or subscribe for, or any offer to underwrite or otherwise acquire any shares in
the Company or any other securities, nor shall they or any part of them nor the fact of their distribution or
communication form the basis of, or be relied on in connection with, any contract, commitment or investment
decision in relation thereto, nor does it constitute a recommendation regarding the securities of the Company.

3. Company Background
3
! VeriTeQ originated as a private company founded
in 2011 to acquire and develop core implantable
RFID intellectual property for healthcare
! Acquired/licensed/developed 100+ patents (issued or
pending)
! Multiple regulatory clearances: FDA and CE Mark
! Completed share exchange agreement with
DigitalAngel Corporation on July 8, 2013;
company changed its name toVeriTeQ
! VeriTeQ shareholders own ~88% of resulting company
! Closed $1.5m bridge financing on Nov. 13
! Ticker changed to “VTEQ” on Nov. 19

4. Unique Value Proposition
4
! In July 2012, the Healthcare Safety and InnovationAct was signed into law and in Sept.
2013, the FDA issued a Final Rule requiring all medical devices in the U.S. that are re-
usable and re-processed to carry a unique device identifier, or UDI, with direct part
marking
! VeriTeQ’s FDA cleared UDI, called Q Inside SafetyTechnology, can serve as a direct
part marking to help device manufacturers comply with the Final Rule, and can also
identify a permanent implantable medical device, in vivo, on demand
! Q Inside SafetyTechnology goes beyond device identification and provides clinical and healthcare
benefits via customizable software and data analytics
! VeriTeQ also offers FDA cleared radiation dose measurement technologies to protect
patients undergoing cancer treatment
! VeriTeQ’s implantable and wearable dosimetry products provide radiation levels from the patient
to help prevent overdose and under-dose

5. Company Overview
5
! VeriTeQ provides proprietary, innovative healthcare solutions for
Unique Device Identification and Bio-Sensing/Radiation Dosimetry
applications
! CoreTechnology: implantable radio frequency (RF) microchip technology
! Cleared by the FDA as the Predicate Class II medical device in the industry
! UDI products enable access to UDI information, in-situ, on demand, at
the point of use
! A leading industry position to enable compliance with FDA Final Rule
! Q Inside SafetyTechnology also enables data analytics for evidence-based
medicine
! Bio-sensing technologies for radiation dosimetry provide real-time
measurements of received radiation dose from the patient, not the
machine
! External and internal product applications
! Helps prevent radiation overdosing and under-dosing

6. Lead Business Areas
6
Medical Device
UDI/Q Inside
SafetyTechnology
Breast Implants
and Breast
Implant Sizers
Vascular Ports
Other Reusable
and Implantable
Medical Devices
Bio-Sensing/
Radiation
Dosimeter
Technologies
External
Radiation
Dosimeter
Implantable
Radiation
Dosimeter

7. TheVeriTeQ UDI System
Medical Devices with
Inside
SafetyTechnology
7

8. FDA Final Rule
8
! The Final Rule requires devices intended to be used more than once and intended to undergo any
form of reprocessing before each use, i.e. re-useable/reprocessed medical devices to have a direct
part marking (vs. basic labeling on device packaging)
! Requires the direct part marking to be provided through either or both of the following:
! Easily readable plain text;
! Automatic Identification and Data Capture (AIDC), or an alternative technology, that will provide the UDI
of the device on demand
Benefits of a UDI System
! Allows more accurate reporting and analysis of adverse events to quickly identify problem devices
! Reduces medical errors by quickly and accurately identifying a device and its characteristics
! Provides a standardized identifier that allows manufacturers, distributors and healthcare facilities
to more effectively manage medical device recalls
! Provides a consistent way to enter information about devices in electronic health records and
clinical information systems
! Provides a foundation for a global, secure distribution chain, helping to address counterfeiting and
diversion and prepare for medical emergencies

9. — Implantable RFID
Microchips
— Patented and FDA
cleared
— Provides the primary
key information
— Pocket Readers
— Patented and FDA
Cleared
— Pocket Reader
— Pocket Reader EX
VeriTeQ’s UDI System: Inside
— Database
— Customization
for device
manufacturer
— Informatics
— Integration with
FDA database
9

10. UDI Business Model
10
! VeriTeQ acts primarily as a supplier of its proprietary microchips and readers to
medical device manufacturers
! Manufacturers incorporateVeriTeQ’s products into their manufacturing
processes/distribution strategy (to hospitals, physicians, etc.)
! Price per chip = $10-12; gross margin per chip = 65 - 75% margins
! Price per reader = $300-500; gross margin per reader = 40 – 60% margins
! VeriTeQ also provides development services to medical device manufacturers
! Primary development areas include design and manufacturing process to include chip
in their medical device, i.e. new encasement technologies such as special polymers
and heat resistant microchips
! Avg. price for development per manufacturer = $250,000; gross margin = 50%
! Data services include database connectivity to manufactured microchips,
application software to collect microchip/medical device model implanted,
FDA data base registry and informatics analytics. Priced on per project
development ranging from $25,000 to several hundred thousand dollars

11. Targeted Customers
11
Breast Implant/
Sizers
Manufacturers
Vascular Port
Manufacturers
Artificial Joint/
Sizers
Manufacturers
HeartValue Sizers,
Endo/ Surgical
Equipment

12. Breast Implants
12
! VeriTeQ’s Q Inside SafetyTechnology can be embedded within
breast implants and sizers to automatically identify the medical
device in situ or after re-sterilization.
! Ex-US:Agreement with Establishment Labs/Motiva
! Leading global breast, body and facial aesthetic company that
manufactures advanced silicone-filled breast implants, marketed
under the Motiva Implant Matrix brand name
! Manufacturing completed and CE Mark certifications achieved
! Launch Q1-2014 (EU and UK)
! US: Market leading breast implant manufacturer is testing
feasibility to integrate the Q Inside in its silicone implants and
sizers
! Discussions ongoing with the two leading global breast implant
manufacturers regarding need to identify their sizers to comply
with FDA Final Rule
! Company estimates sizer market at 600,000 devices annually

13. Vascular Ports
13
! Partnership with Medcomp (a leading manufacturer of vascular
ports) to utilize Q Inside for Medcomp’s FDA-cleared vascular
ports
! $3 million initial contractual PO commitment from Medcomp
! Enables accurate device identification and medication dosage
! Hospital studies expected to begin at:
! Northwestern Memorial in Chicago
! NewYork-Presbyterian – University Hospital of Columbia and Cornell in
NY
! Cleveland Clinic in Cleveland, OH or MDAnderson Cancer Center in
Houston,TX
! Medcomp /VeriTeQ targeting to set clinical UDI standard to
incentivize other port manufacturers to use Q Inside – e.g. C.R.
Bard, Smiths Medical, etc.

14. Artificial Joints and Sizers
14
! Identification of implantable and reusable medical devices such as
sizers used in joint replacements (subject to Final Rule)
! Artificial hips in the U.S.:
! Number of procedures: 230,000
! Total annual expenditure: $10.5 billion
! Average cost per procedure: $45,000
! Major manufacturers: Zimmer (24%), Stryker, DePuy/J&J, Biomet,Wright
Medical
! Artificial knees in the U.S.
! Number of procedures: 543,000
! Total annual expenditure: $12 billion
! Average cost per procedure: $22,000
! Major manufacturers: Zimmer (24%), Depuy/J&J, Stryker, Biomet, Smith &
Nephew
! Active initial meetings/dialog with lead target device
manufacturers
! Clinical benefits: Q Inside SafetyTechnology allows for immediate data
retrieval; can help quickly resolve adverse event reporting and recalls
As published on July 18,2011 in 24/7Wall St.’s Eleven Most Implanted Medical Devices In America

15. VeriTeQ Bio-Sensors
In Situ Measurement of
Radiation Dosages
15

16. Sensing Technologies
16
VeriTeQ owns Patent 7,125,382 for an “Embedded Bio-Sensor
System,” a biological sensor on the end of a radio frequency chip
! Temperature (current)
! Radiation levels (current)
! Blood oxygen (future)
! Pulse (future)
! Medication levels (future)
! i.e. post surgery
! Glucose (licensed to a third party)
! Others

17. VeriTeQ Dosimetry
OneDose
ExternalTechnology
Q Inside SmartMarker
ImplantableTechnology
Radiation DoseVerification
17

18. Maximize
Tumor Control
(High Dose)‫‏‬
Minimize
Healthy Tissue
Toxicity
(Low Dose)‫‏‬
The greatest challenge for radiation therapy or any cancer therapy is to attain the
highest probability of cure with the least morbidity.1
1) Bucci MK,Bevan A and Roach M.Ca Cancer J Clin 2005;55:117-134
Objective of the Radiation Oncologist
18

19. Patient Safety & Radiation Overdose
19
! 2013: #3 Unnecessary exposures and
radiation burns from diagnostic
radiology procedures
! 2012: #2 Exposure hazards from
radiation therapy and CT
! 2011: #1 Radiation overdose and
other errors during radiation therapy
! 2009-10: #4 CT radiation dose
! 2008: #8 CT radiation dose
! 2007: #5 Radiation therapy errors
According to the ECRI Institute, radiation or CT overdose make the list of theTop
10Technology Hazards each year going back at least five years

20. VeriTeQ OneDose ®
20
! OneDose® is an FDA-cleared single-use, external dosimetry system used in
the radiation oncology suite to verify radiation dose quickly and conveniently
at the skin level
! Significant IP protection
! CE Mark to market products in the E.U.
! OneDose is the only wireless, pre-calibrated, disposable, surface sensor on
the market that provides an instant readout of the dose delivered
! Reimbursement rate per patient (4-6 dosimeters used during treatment)
ranges between $260 and $380
! In 2010, 1.1 million patients received radiation therapy in the U.S.* with
new indications for use in CT and fluoroscopy markets
! Researchers at the National Cancer Institute estimate that 29,000 future cancer
cases could be attributed to the 72 million CT scans performed in the country in
2007
! Over 5 million fluoroscopic procedures performed annually in the U.S.**
* According to a study published by IMV Medical Information Division
**National Council on Radiation Protection and Measurements,report No.168 (2010)

21. Q Inside SmartMarker
21*Source = ASTRO,American Society of Radiation Oncology
! World’s first and only implantable wireless radiation dosimeter; FDA
cleared for use in prostate and breast cancer radiotherapy
! Enables radiation oncologists to immediately measure the dose of radiation
penetrating a tumor or tumor area
! Cleared for use in photon external beam and hypo-fractionated treatment protocols
! Potential additional new indications for use include lung, colorectal and pancreatic
cancer
! Only device that confirms radiation dose delivered to tumor
! Can also be used as a fiducial marker for localization of the tumor
! Device is reimbursable by both Medicare and private insurance
! FDA cleared & CE mark; significant patent protection
! Approximately 81,580 patients receive seed implants per year in the U.S. and
more than 425,000 patients are diagnosed with prostate and breast cancers
total each year in the U.S.*

22. Bio-Sensor Business Model
22
! To be sold to radiation oncology centers in the U.S. and E.U.
! Radiation oncologists, therapists, physicists, dosimetrists
! Over 4,400 radiation oncologists in the U.S., with 4 states representing 33% of the
U.S. market
! To be sold through direct sales, worldwide distribution partners, product
specific website, trade associations
! Price for One Dose Reader Kit = $499; gross margin = 80%
! Price for Q Inside SmartMarker Kit = $1,200; gross margin = 80%
! Potential distribution partners:

23. Intellectual Property
23
VeriTeQ has a robust portfolio of more than 100 patents, patents pending and licenses in the U.S.
and abroad. VeriTeQ’s foundation patents are an Embedded Bio-Sensor System on the end of a RF
microchip (Patent 7,125,382 issued in 2006), and the use of implantable sensors for monitoring
tumors in oncology applications (Patent 6,402,689 issued in 2002). A partial list of the Company’s
key patents follows.
Patent No. Title
7,125,382 Embedded Bio-Sensor System
6,402,689 Methods, Systems andAssociated Implantable Devices for Dynamic Monitoring of Physiological and Biological Properties ofTumors
7,378,056 Methods, Circuits, and Compositions of Matter for InVivo Detection of Biomolecule Concentrations Using FluorescentTags
7,011,814 Systems, MethodsAnd Devices For InVivo Monitoring OfA Localized ResponseViaA RadiolabeledAnalyte InA Subject
7,479,108 Implantable Sensor Housing, Sensor UnitAnd Methods For FormingAnd UsingThe Same
7,495,224 Disposable Single-Use External Dosimeters For Use In RadiationTherapies
7,966,054 Disposable Single-Use External Dosimeters For Detecting Radiation In FluoroscopyAnd Other Medical Procedures/Therapies
7,491,942 Disposable Single-Use Internal Dosimeters For Detecting Radiation In Medical Procedures/Therapies
7,010,340 Methods, Systems, and Computer Program Products for Providing Dynamic Data of Positional Localization ofTarget Implants
7,510,699 InVivo Fluorescence Sensors, Systems,And Related Methods Operating In Conjunction with Fluorescently Labeled Materials
7,557,353 Single-Use External Dosimeters for Use in RadiationTherapies and Related Methods, Systems and Computer Program Products

24. Leadership Team
24
Scott R. Silverman
Chairman & CEO
Mr. Silverman has been Chairman and CEO ofVeriTeQ since its inception in Dec. 2011. He served as Chairman and CEO of
PositiveID Corp. (OTC:PSID) from 2008 toAug. 2011, and Chairman and CEO ofVeriChip Corp. (NASDAQ:CHIP) from Dec.
2006 to Jul. 2008. He was Chairman of DigitalAngel Corp. from 2003 to 2007. From 2003 to 2006, Mr. Silverman served as
Chairman and CEO ofApplied Digital Solutions (NASDAQ:ADSX). Mr. Silverman is an attorney licensed to practice in NJ and
PA, and has more than 15 years of executive experience with technology companies. He is a graduate of the University of
Pennsylvania andVillanova School of Law.
Randolph K. Geissler
President
Mr. Geissler has been President ofVeriTeQ since July 2012. He developed the implantable microchip, with more than 150
million microchips implanted in animals for identification and tracking. He previously served as CEO of GeisslerTechnologies
(2004 - 2008) when he sold the company's product development pipeline. Prior to that, he served as CEO of DigitalAngel Corp.
(Amex: DOC) (2000 - 2003) and Destron Fearing (Nasdaq: DFCO) (1993 - 1999), a company he founded. He has taken
companies public and has broad experience in product development, electronic miniaturization, application of advanced
technologies in new markets, and extensive experience in establishing strategic intellectual property and patent portfolios.
Michael Krawitz
Chief Legal and
Financial Officer
Mr. Krawitz was most recently the CEO of Pear Energy, a renewable energy company that finances renewable energy and energy
efficiency projects. He previously served as CEO of Florida Sunshine Investments I, Inc., which manages more than $1 billion
worth of properties throughout the United States. He is also a member of the Company's Board of Directors. Mr. Krawitz earned
a bachelor of arts degree from Cornell University and a Juris doctorate from Harvard Law School.
AllisonTomek
Sr.VP IR &
Corporate
Communications
Ms.Tomek has served as Sr.VP ofVeriTeQ since its inception and has served as Sr.VP, IR and Corp Comm of PositiveID since
January 2007. From Jan. 2007 to Jun. 2008 she was alsoVP of IR atApplied Digital Solutions and DigitalAngel. From 2003 to
2006, Ms.Tomek was Director of IR and Corp Comm atAndrx Corp. (NASDAQ:ADRX). Ms.Tomek is the former President of
the National Investor Relations Institute, South Florida chapter and a current member of its Board.

25. Capitalization
25
Shares
Held
Percent
Ownership
Officers and Directors 6,680,854 71%
Float 2,778,519 29%
TOTAL 9,459,373 100%
Fully diluted 12,417,684

26. Near-Term Goals
26
! Initiate first product release: marketing of Motiva breast
implants with Q Inside SafetyTechnology in EU/UK
! Enter into more partnership/supply agreements post
Final Rule
! Enter into partnership for data analytics platform
development
! Continued expansion of patent portfolio surrounding Q
Inside SafetyTechnology for medical devices
! Additional future partnerships

27. Investment Highlights
27
! Unique industry technology and market position for its Q Inside Safety
Technology unique device identification products
! FDA cleared device that meets the UDI direct marking mandate for reusable medical
devices under the FDA Final Rule provides for “first to market” capability
! IP provides strong competitive position for long term strategic advantage
! Launch of Q Inside breast implants in Q1 2014
! Commercial partnership with Establishment Labs/Motiva for ex-US markets
! Major US manufacturer currently in prototype stage
! Preparing for immediate expansion into markets forVascular Ports and Orthopedic
Implants
! Commercial partnership with MedComp in place
! VeriTeQ Radiation Dosimetry products – ready to move into
commercialization
! Radiation dosimeters used in the treatment of cancer
! Unique patented technologies with multiple regulatory approvals provide
competitive advantage in respective markets

28. Q&A
Thank you!